Mounjaro is a brand-name injectable medication containing tirzepatide, made by Eli Lilly. It was approved by the FDA in 2022 for adults with type 2 diabetes and has since been expanded to include children aged 10 and older. What sets it apart from older diabetes drugs is its dual action: it mimics two gut hormones simultaneously, producing stronger blood sugar control and significant weight loss compared to medications that target only one.
How Mounjaro Works in the Body
Your gut naturally releases two hormones after you eat: GLP-1 and GIP. Both signal your pancreas to produce more insulin when blood sugar rises. Mounjaro is the first medication that activates the receptors for both of these hormones at once, and the combination produces a stronger insulin response than either hormone triggers alone.
Beyond insulin, these two pathways affect the body in several overlapping ways. They slow down how quickly food leaves your stomach, so sugar enters your bloodstream more gradually. They reduce your appetite by acting on hunger signals in the brain. And they suppress glucagon, a hormone that tells your liver to release stored sugar. The net effect is lower blood sugar after meals, less hunger between meals, and a meaningful reduction in body weight over time.
What Mounjaro Is Approved to Treat
Mounjaro’s FDA-approved use is improving blood sugar control in people with type 2 diabetes, alongside diet and exercise. It is not approved for type 1 diabetes or for weight loss on its own. However, Eli Lilly sells the exact same active ingredient, tirzepatide, under a separate brand name called Zepbound for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition like high blood pressure or sleep apnea. Zepbound also carries an approval for moderate to severe obstructive sleep apnea in adults with obesity.
The distinction matters mainly for insurance coverage. Mounjaro is billed as a diabetes medication, while Zepbound is billed as a weight management medication, and coverage varies widely between the two.
Blood Sugar Results From Clinical Trials
Mounjaro was tested across a series of large trials called the SURPASS program. In SURPASS-1, which compared the drug to a placebo, participants on the highest dose (15 mg) saw their A1C drop by 2.11 percentage points. To put that in perspective, an A1C reduction of even 1% is considered clinically meaningful. Across all the trials, A1C reductions ranged from 1.24% to 2.11% compared to placebo.
Mounjaro also outperformed several existing treatments head-to-head. In SURPASS-2, it lowered A1C by an additional 0.15 to 0.45 percentage points more than semaglutide (the active ingredient in Ozempic), depending on the dose. In trials against long-acting insulins, the gap was even wider, with Mounjaro beating insulin by 0.59 to 1.14 percentage points.
Weight Loss Effects
Weight loss is one of Mounjaro’s most notable effects, even in people taking it for diabetes. In the SURMOUNT-1 trial, which studied tirzepatide specifically for weight management in adults with overweight or obesity, participants lost an average of 16.0% of their body weight on the 5 mg dose, 21.4% on the 10 mg dose, and 22.5% on the 15 mg dose. For someone weighing 250 pounds, that highest dose translates to roughly 56 pounds lost.
How It’s Taken
Mounjaro is a once-weekly injection using a prefilled pen. You can inject it in your abdomen or thigh. If someone else is giving you the injection, the back of the upper arm is also an option. You pick the same day each week, though the exact time of day doesn’t need to be consistent.
The dose starts low and increases gradually. You begin at 2.5 mg weekly for four weeks, then move up to 5 mg. If your blood sugar still needs improvement, your prescriber can raise the dose in 2.5 mg steps every four weeks or longer, up to a maximum of 15 mg per week. This slow escalation helps your body adjust and reduces the severity of side effects.
The pens should be stored in the refrigerator (36°F to 46°F), but you can keep one at room temperature below 86°F for up to 21 days if needed, which is useful for travel.
Common Side Effects
Digestive issues are the most frequent side effects, and they tend to be worst during the early weeks and dose increases. In a meta-analysis pooling data from multiple trials, about 1 in 5 people taking Mounjaro experienced nausea (20.4%), compared to about 1 in 10 on a placebo or other treatments. Diarrhea affected 16.2% of users, and decreased appetite occurred in 9.6%.
Other common gastrointestinal effects included:
- Vomiting: 9.1% of users
- Indigestion: 7.1% of users
- Constipation: 2.5% of users
For most people, these effects are mild to moderate and ease up as the body adjusts. The gradual dose increases are specifically designed to make this transition smoother.
Important Safety Warnings
Mounjaro carries a boxed warning, the FDA’s most serious label, regarding thyroid tumors. In animal studies, tirzepatide caused thyroid C-cell tumors in rats at doses similar to what humans take. Whether this risk applies to people is unknown. Because of this uncertainty, Mounjaro is not an option for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, trouble swallowing, difficulty breathing, or persistent hoarseness.
The medication has not been studied in people with severe gastroparesis (a condition where the stomach empties very slowly) and is not recommended for them, which makes sense given that the drug itself slows gastric emptying. It also hasn’t been studied in people with a history of pancreatitis. Gallbladder problems, including gallstones, occurred in 0.6% of Mounjaro users in clinical trials compared to 0% on placebo, a small but real increase.
Anyone with a known serious allergy to tirzepatide or any ingredient in the pen should not use Mounjaro, as cases of severe allergic reactions including anaphylaxis have been reported.